Thus, IFN-γ can modify all the DNCB-induced AD-like changes observed in this study: clinical symptoms, attenuation of skin barrier function, immune cell infiltration, and changes in serum IgE, IgG1 and IgG2a levels and skin Th1 and Th2 cytokine mRNA expressions. The gene discussed is IFNG; the disease is Alzheimer disease.